MaxCyte, Inc.: updates and filings

MXCTNASDAQHealthcare · Services-Commercial Physical & Biological Research

Price

$1.19

November 13, 2026Market cap $127M

DCF calculator

What Ploutos Investor adds for MaxCyte

Part of Ploutos Investor, €9.99 a month

See the plans

The full history: 7 fiscal years, from 2019
The estimated fair value, with its range and its certainty
The full analysis, 18 a month
More questions to the chat on its filings
Excel with every year
An email when it reports, changes its dividend or an officer buys

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 88 daysAround Feb 11, 2027 · for Q4 2026

last Oct 14, 2026next Feb 11, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

November 2026

October 2026

14WedResultsResults of operationsDocument

August 2026

June 2026

May 2026

March 2026

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 25, 2026 latest annualNov 10, 2026 latest quarterly

Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
Form10-Q
Nov 10, 2026Material agreement entered, results of operations, unregistered sale of shares, Regulation FD disclosure
Form8-K
Nov 2, 2026Over-5% holder statement (active)
FormSCHEDULE 13D
Oct 15, 2026Over-5% holder statement (active)
FormSCHEDULE 13D
Oct 14, 2026Results of operations
Form8-K
Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
Form10-Q
Aug 12, 2026Results of operations, Regulation FD disclosure
Form8-K
Aug 4, 2026Over-5% holder statement (active)
FormSCHEDULE 13D
Jul 29, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Jun 17, 2026Shareholder vote
Form8-K
Jun 16, 2026Delisting notice
Form8-K
May 14, 2026Over-5% holder statement (active)
FormSCHEDULE 13D
May 13, 2026Quarterly reportfor the period to Mar 31, 2026
Form10-Q
May 12, 2026Results of operations, Regulation FD disclosure
Form8-K
Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025
FormARS
Apr 29, 2026Additional annual meeting material
FormDEFA14A
Apr 29, 2026Annual meeting proxy statement
FormDEF 14A
Apr 15, 2026Shares registered for employees
FormS-8
Apr 10, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Mar 27, 2026Officer or director change
Form8-K
Mar 27, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Mar 25, 2026Annual reportfor the period to Dec 31, 2025
Form10-K
Mar 24, 2026Results of operations, Regulation FD disclosure
Form8-K
Mar 20, 2026Delisting notice
Form8-K
Feb 17, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A

Filed	Form	What it is	Filing
Nov 10, 2026	10-Q	Quarterly reportfor the period to Sep 30, 2026	Document
Nov 10, 2026	8-K	Material agreement entered, results of operations, unregistered sale of shares, Regulation FD disclosure	Document
Nov 2, 2026	SCHEDULE 13D	Over-5% holder statement (active)	Document
Oct 15, 2026	SCHEDULE 13D	Over-5% holder statement (active)	Document
Oct 14, 2026	8-K	Results of operations	Document
Aug 13, 2026	10-Q	Quarterly reportfor the period to Jun 30, 2026	Document
Aug 12, 2026	8-K	Results of operations, Regulation FD disclosure	Document
Aug 4, 2026	SCHEDULE 13D	Over-5% holder statement (active)	Document
Jul 29, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Jun 17, 2026	8-K	Shareholder vote	Document
Jun 16, 2026	8-K	Delisting notice	Document
May 14, 2026	SCHEDULE 13D	Over-5% holder statement (active)	Document
May 13, 2026	10-Q	Quarterly reportfor the period to Mar 31, 2026	Document
May 12, 2026	8-K	Results of operations, Regulation FD disclosure	Document
Apr 29, 2026	ARS	Annual report to shareholdersfor the period to Dec 31, 2025	Document
Apr 29, 2026	DEFA14A	Additional annual meeting material	Document
Apr 29, 2026	DEF 14A	Annual meeting proxy statement	Document
Apr 15, 2026	S-8	Shares registered for employees	Document
Apr 10, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Mar 27, 2026	8-K	Officer or director change	Document
Mar 27, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Mar 25, 2026	10-K	Annual reportfor the period to Dec 31, 2025	Document
Mar 24, 2026	8-K	Results of operations, Regulation FD disclosure	Document
Mar 20, 2026	8-K	Delisting notice	Document
Feb 17, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 14, 2004.

And 184 filings on insiders' shares142 Form 4, 21 Form 144 and 21 Form 3 since Jul 29, 2021. Their trades are on the Ownership tab.

The full analysis

What do MaxCyte's filings show?

The filings are where every one of MaxCyte's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

A fair value range built from the filings
Earnings quality, debt and red flags
Insider and institutional moves
The case for and the case against

All filings on EDGAR

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.